@ascocancer.bsky.social
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. The world’s leading professional organization representing more than 50,000 oncology professionals caring for people with cancer.
Congratulations to our CMO Dr. @jrgralow.bsky.social on receiving the 2025 National Cancer Grid Lifetime Achievement Award in Oncology! The award was presented at the NCG Annual Meeting in Mumbai, India, for her longstanding contributions to cancer care, research, and global oncology.
05.08.2025 14:00 — 👍 3 🔁 0 💬 0 📌 0
Attending the National Cancer Grid annual meeting in Mumbai and learning about the terrific projects being undertaken to improve cancer care and control in India. @ascocancer.bsky.social is proud to to be a partner. @cspramesh.bsky.social
03.08.2025 05:45 — 👍 5 🔁 2 💬 0 📌 0"Our goal is to ensure the best cancer care for every patient, every cancer, everywhere." Dr. Eric Small @ascocancer.bsky.social president and @ucsanfrancisco.bsky.social physician | connection.asco.org/do/science-m...
04.08.2025 19:28 — 👍 3 🔁 1 💬 0 📌 0Gather with peers and friends who share your dedication to addressing quality, safety, and efficiency in #CancerCare delivery and join us in Chicago, October 10-11, for #ASCOQLTY25. Early registration closes on Sept. 3. Reserve your space today: brnw.ch/21wUEIk
04.08.2025 16:04 — 👍 3 🔁 3 💬 0 📌 0
🎙 @realbowtiedoc.bsky.social & @rsedhom.bsky.social of @pennmedicine.bsky.social discuss a new strategy called precision palliative care – getting the right support to the right patient at the right time – on the latest episode of the #ASCODailyNews Podcast: brnw.ch/21wUB0b
01.08.2025 17:19 — 👍 4 🔁 2 💬 0 📌 0
#ASCOAdvocacy applauds the Senate Appropriations Committee's bipartisan vote yesterday to increase funding for NIH and NCI. Now, we need the full Senate & House to follow suit.
Urge your lawmakers to support this funding. Act now: brnw.ch/21wUvvx
Submit your entry into #JCO's first Art of Oncology Narrative Medicine Contest for early career oncologists. Now through August 31, 2025.
Learn more at brnw.ch/21wTrj7
#ASCOAdvocacy & the American Medical Association released an issue brief on mandatory white bagging & welcome opportunities to partner w/ state societies on this issue. 12 states have passed legislation banning mandatory white & brown bagging & we hope to see more!
➡️ brnw.ch/21wUzgG
Investing in #CancerResearch saves lives! Urge your lawmakers to support FY26 funding for the National Institutes of Health & National Cancer Institute, ahead of @senateapprops.bsky.social & Senate GOP Appropriations Committee meeting on the LHHS spending bill. #ASCOAdvocacy
Act: brnw.ch/21wUvyu
A pleasure and an honor to join @fumikochino.bsky.social & Dr. Ethan Ludmir in this @ascocancer.bsky.social conversation on incomplete reporting and toxicity- minimizing language in oncology! 💗
28.07.2025 23:53 — 👍 7 🔁 4 💬 0 📌 0
#NACLC25 is open! Registration & abstracts are live for Dec 5–7, 2025, in Chicago.
Hear from co‑chairs @kamarronemd.bsky.social & Ramesh Rengan, MD, PhD, FASTRO on Lung Cancer Considered—insights, highlights & why you should be there.
🎧 bit.ly/NACLC25Preview
#LungCancer @ascocancer.bsky.social
ICYMI: In the era of EV plus pembro, where does radical cystectomy fit into treatment plans for patients with urothelial carcinoma? Dr. Sia Daneshmand provides a detailed overview for #ASCODailyNews: brnw.ch/21wUqrz
25.07.2025 14:10 — 👍 1 🔁 1 💬 0 📌 0
ASCO Quality Care Symposium ORVING SOLUTIONS, IMPLEMENTING CHANGE October 10-11, 2025 | Chicago, IL & Online | #ASCOQLTY25 Addressing Quality, Safety, and Efficiency in Cancer Care Delivery Dear Colleague, As Chair of the 2025 ASCO Quality Care Symposium, I am overjoyed to personally invite you and your colleagues to join me at the premier meeting dedicated to advancing the quality, safety, and efficiency of cancer care delivery. This Symposium offers a unique opportunity to connect and collaborate with a dynamic community of professionals committed to
A strange thing happened.
I emailed myself to personally invite me to the conference that I am chairing.
Excited to see me (and hopefully you!) at #ASCOQLTY25 😂 @ascocancer.bsky.social
www.asco.org/quality
A new Journal of Clinical Oncology report calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the "maximum tolerated dose" may be outdated, harmful to patients, & ill-suited for modern cancer therapies. Learn more: brnw.ch/21wUp7Q
24.07.2025 20:37 — 👍 4 🔁 2 💬 0 📌 0
The updated Oncology Medical Home Standards are now live in JCO Oncology Practice. A joint initiative of ASCO & the Community Oncology Alliance, the standards were introduced in 2021 & provide a framework for onc practices to deliver high-quality, patient-centered cancer care ➡️ brnw.ch/21wUp2H
24.07.2025 19:25 — 👍 2 🔁 0 💬 0 📌 0![Screening for Financial Toxicity and Health-Related Social Risks in Patients With Gl Cancer: Results From a Large
Cancer Center
PURPOSE Patients with GI cancers often face significant financial toxicity (FT) and
health-related social risks (HRSRs), yet best practices for screening remain unclear. This study aimed to evaluate the prevalence of FT and HRSR and identify associated factors.
METHODS From June 2022 to August 2023, patients were screened using the Compre-hensive Score for Financial Toxicity (COST), patient-reported HRSR (eg, housing, food insecurity), and quality of life (QOL). Multivariate regressions were used to assess predictors of FT and HRSR, adjusting for several variables.
RESULTS Among 8,335 patients with GI cancer, 45% had a COST score of <26, indicating FT. In adjusted linear regression, FT was associated with racial/ethnic minority status (B, 4.20; P < .001), advanced disease (stage III (B, 1.33; P < .001); IV [B,
1.56; P < .001)), recent treatment (B, 3.23; P < .001), and anal (B, 1.97; P = .003),
esophageal (B, 1.66; P = .005), or hepatobiliary cancer (B, 1.05; P = .031). Older
age (≥65 years [B, -5.17; P < .001)), higher income ($100,000-$200,000 (B, -181; P < .001); >$200,000 [B, -3.80; P < .001)), and private insurance (B, -1.70; P < .001) were protective. Twenty-eight percent reported at least one HRSR. HRSRs were associated with minority status (odds ratio [OR], 2.14;
P < .001), advanced disease (stage III [OR, 1.31; P = .001); IV[OR, 1.24; P = .010)),
recent treatment (OR, 1.20; P = .001), and gastric cancer (OR, 1.25; P = .027).
Lower HRSR was associated with older age (OR, 0.59; P < .001), higher income ($100,000-$200,000 (OR, 0.66; P < .001); >$200,000 (OR, 0.48; P < .001)), and private insurance (OR, 0.64; P < .001). Sex was not a predictor. Worst FT was associated with decreased QOL (B, -0.98; P < .001) and reduced medication adherence (B, 0.11; P < .001).
CONCLUSION High levels of FT and HRSR were observed in patients with GI ca…](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:bezfqro7gz4mmrf3yx5wi7gn/bafkreigrnqgkbag2uonhhredzkyqn5kx4ofbrccmoxznu2gaefaai3m3vq@jpeg)
Screening for Financial Toxicity and Health-Related Social Risks in Patients With Gl Cancer: Results From a Large Cancer Center PURPOSE Patients with GI cancers often face significant financial toxicity (FT) and health-related social risks (HRSRs), yet best practices for screening remain unclear. This study aimed to evaluate the prevalence of FT and HRSR and identify associated factors. METHODS From June 2022 to August 2023, patients were screened using the Compre-hensive Score for Financial Toxicity (COST), patient-reported HRSR (eg, housing, food insecurity), and quality of life (QOL). Multivariate regressions were used to assess predictors of FT and HRSR, adjusting for several variables. RESULTS Among 8,335 patients with GI cancer, 45% had a COST score of <26, indicating FT. In adjusted linear regression, FT was associated with racial/ethnic minority status (B, 4.20; P < .001), advanced disease (stage III (B, 1.33; P < .001); IV [B, 1.56; P < .001)), recent treatment (B, 3.23; P < .001), and anal (B, 1.97; P = .003), esophageal (B, 1.66; P = .005), or hepatobiliary cancer (B, 1.05; P = .031). Older age (≥65 years [B, -5.17; P < .001)), higher income ($100,000-$200,000 (B, -181; P < .001); >$200,000 [B, -3.80; P < .001)), and private insurance (B, -1.70; P < .001) were protective. Twenty-eight percent reported at least one HRSR. HRSRs were associated with minority status (odds ratio [OR], 2.14; P < .001), advanced disease (stage III [OR, 1.31; P = .001); IV[OR, 1.24; P = .010)), recent treatment (OR, 1.20; P = .001), and gastric cancer (OR, 1.25; P = .027). Lower HRSR was associated with older age (OR, 0.59; P < .001), higher income ($100,000-$200,000 (OR, 0.66; P < .001); >$200,000 (OR, 0.48; P < .001)), and private insurance (OR, 0.64; P < .001). Sex was not a predictor. Worst FT was associated with decreased QOL (B, -0.98; P < .001) and reduced medication adherence (B, 0.11; P < .001). CONCLUSION High levels of FT and HRSR were observed in patients with GI ca…
Clothing Repairs to Home Food Medications Housing Transportation 0% 9% 11% 11% 12% 12% Proportion of Patients (%, N = 8,335) FIG 1. HRSRs among patients with Gl cancers. Proportion of patients with Gl cancer who self-reported difficulty in affording at least one essential need and were identified as having a specific HRSRs. HRSR, health-related social risks.
In this analysis of >8k with #GIcancers:
👉45% (n=3,764) had a COST score of <26, indicating #financialToxicity
👉28% (n=2,321) reported at least 1 health related social risk... including > 1️⃣in🔟 who couldn't afford 🍔🥗, 🛏️🏡, or 🚗🚐
@ascocancer.bsky.social
ascopubs.org/doi/pdfdirect/10.1200/OP-25-00218
The draft guideline protocol, Perioperative Treatment in RCC at High-Risk of Recurrence, is now available for open comment. Provide your feedback to us by August 1.
Learn more: brnw.ch/21wUmBc
“When choosing cancer therapies, people should not have to choose between being alive & living”
Toxicity minimizing language ("safe” & “tolerable”) are subjective & can downplay QOL limiting side effects from treatment.
🚨New @ascocancer.bsky.social Podcast is live today!
@coffeemommy.bsky.social
Improving #OncologyCare! Check out our latest standards update on the Oncology Medical Home.
Read the full article: brnw.ch/21wUjje
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.
Learn more about FASCO distinction: brnw.ch/21wUiSd
Best conference for #EarlyCareer folks interested in #GIonc. Great #mentorship abounds and intimate engagement compared to #ASCOAM. Definitely check it out!
19.07.2025 08:46 — 👍 2 🔁 2 💬 0 📌 0
Meet the moment & help shape the future of GI cancer care by submitting an abstract to #GI26. Whether you have a study in progress or late-stage clinical trial, this meeting offers oral & poster presentation opportunities across all disciplines & GI disease sites.
Submit today: brnw.ch/21wUg0p
🚨 Just issued! Our new living guideline update on therapy for Stage IV #NSCLC without driver alterations is here. Stay up-to-date with the latest recommendations.
Read the full article: brnw.ch/21wUfEC
🚨 Just issued! Our new living guideline update on therapy for Stage IV #NSCLC with driver alterations is here. Stay up-to-date with the latest recommendations.
Read the full article: brnw.ch/21wUel6
This state session #ASCOAdvocacy has been busy! By working with the State Affiliates and coalition partners, we engaged on issues affecting cancer patients and care providers state-by-state.
See what we've done in the first half of 2025: brnw.ch/21wUdXd
New draft guideline alert! 🚨 Our "Systemic Treatment of Thyroid Guideline" is open for comments until July 30.
Share your feedback: brnw.ch/21wUcv2
Drs. Hope Rugo of City of Hope, Keri Brenner of Stanford Medicine, & Mikolaj Slawkowski-Rode of Oxford University, discuss strategies to help clinicians respond to suffering in a more patient-centered and therapeutic way on the ASCO Education #BytheBook Podcast.
Listen now: brnw.ch/21wUbRl
The 2026 Medicare physician fee schedule proposal includes a nearly 4% reimbursement increase, new efficiency adjustment, telehealth changes, & more provisions that will impact #cancer care.
Read the initial #ASCOAdvocacy analysis: brnw.ch/21wUaCt
ICYMI: Dr. Robert A. Figlin, Oncology News Central's Peer-Spectives podcast host, spoke to our CEO @cliffordhudis.bsky.social about challenges academic oncologists face, incl burnout & unrealistic job expectations & how to better support them.
Listen Now: brnw.ch/21wU8JM
New draft update protocol alert! 🚨 Our "PARP Inhibitors in the Management of Ovarian Cancer" is open for comments until July 21.
Share your feedback ➡️ brnw.ch/21wU0Vh
#OvarianCancer #PARPInhibitors
